Global coagulation tests: Their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 11, 2014, Pages 1615-1623

  Dinkelaar, Jasper ^a   Patiwael, Sanne ^b   Harenberg, Job ^c   Leyte, Anja ^a   Brinkman, Herm Jan M ^b  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

apixaban; blood coagulation tests; clotting time; dabigatran; reversal of oral anticoagulation; thrombin generation; thromboelastography

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; PROTHROMBIN COMPLEX; THROMBIN; THROMBOPLASTIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; HUMAN; PROTHROMBIN TIME; REACTION TIME; THROMBOELASTOGRAPHY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; PARTIAL THROMBOPLASTIN TIME; PROCEDURES;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; FACTOR XA; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES; THROMBELASTOGRAPHY; THROMBIN;

EID: 84908109518     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0307     Document Type: Article

References (28)

1. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogné JM, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013;110:723-31
2. Tripodi A. The laboratory and the direct oral anticoagulants. Blood 2013;121:4032-5
3. Harenberg J, Du S, Krämer S, Giese C, Schulze A, Weiss C, et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. Semin Thromb Hemost 2013;39:66-71
4. Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 2014;111:189-98
5. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9
6. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012;10:1841-8
7. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012;116:94-102
8. Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol 2013;168:4228-33
9. Perzborn E, Heitmeier S, Laux V, Buchmüller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 2014;113:671-81
10. Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJ, Leyte A. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban. J Thromb Haemost 2013;11:1111-8
11. Grottke O, van Ryn J, Spronk HM, Rossaint R. Prothrombin complex concentrates and a specific antidote to dabigatran are effective exvivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care 2014;8:R27
12. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC, Sanz VV, et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 2013;8:e78696
13. Perzborn E, Gruber A, Tinel H, Marzec UM, Buetehorn U, Buchmueller A, et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013;110:162-72
14. EMA product information Apixaban. Available from: http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002148/WC500107728.pdf. Accessed 3 February, 2014
15. EMA product information Dabigatran. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000829/WC500041059.pdf. Accessed 3 February, 2014
16. Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost 2013;19:522-8
17. Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012;38:16-22
18. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013;76:776-86
19. Schols SE, Feijge MA, Lance MD, Hamulyak K, ten Cate H, Heemskerk JW, et al. Effects of plasma dilution on tissue-factorinduced thrombin generation and thromboelastography: partly compensating role of platelets. Transfusion 2008;48:2384-94
20. Molenaar PJ, Dinkelaar J, Leyte A. Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 2012;50:1799-807
21. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost 2012;38:178-84
22. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25
23. Clemens A, Haertter S, Friedman J, Brueckmann M, Stangier J, van Ryn J, et al. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Cur Med Res Opin 2012;28:195-201
24. Lee FM, Chan AK, Lau KK, Chan HH. Reversal of new, factor specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies. Thromb Res 2014;133:705-13
25. Duchemin J, Pan-Petesch B, Arnaud B, Blouch MT, Abgrall JF. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost 2008;99:767-73
26. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003;23:17-25
27. Butenas S, Mann KG. Kinetics of human factor VII activation. Biochemistry 1996;35:1904-10
28. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996;88: 3432-45.